BeStock  

BioCryst Pharmaceuticals BCRX

US equityMarket cap rank #2720Drug Manufacturers - Specialty & Generic
$7.22 −$0.10 (-1.37%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $7.10 -1.66%
Open$7.26
Prev close$7.32
Day range$7.15 – $7.39
Volume3.85M
Market cap$1.86B
P/E (TTM)–
Dividend yield–

BCRX Stock News

Headlines matching BioCryst Pharmaceuticals or the BCRX ticker, most recent first.

  • Needham Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $16Market news · 9 Sep 2026 · Direct mention
  • J.P. Morgan Maintains BioCryst Pharmaceuticals(BCRX.US) With Hold Rating, Raises Target Price to $13 PositiveMarket news · 30 Sep 2026 · Direct mention
  • BioCryst Pharmaceuticals | 4: Statement of changes in beneficial ownership of securitiesSEC · 3 Sep 2026 · Related
  • BioCryst Pharmaceuticals | 4: Statement of changes in beneficial ownership of securitiesSEC · 3 Sep 2026 · Related
  • BioCryst Pharmaceuticals | 4: Statement of changes in beneficial ownership of securitiesSEC · 3 Sep 2026 · Related
  • BioCryst Pharmaceuticals | 4: Statement of changes in beneficial ownership of securitiesSEC · 3 Sep 2026 · Related
  • BioCryst Pharmaceuticals | 4: Statement of changes in beneficial ownership of securitiesSEC · 3 Sep 2026 · Related
  • RBC Capital Downgrades BioCryst Pharmaceuticals(BCRX.US) to Hold Rating, Cuts Target Price to $11 NegativeMarket news · 10 Sep 2026 · Direct mention
  • H.C. Wainwright Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $32Market news · 7 Aug 2026 · Direct mention
  • RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Cuts Target Price to $13 NegativeMarket news · 6 Aug 2026 · Direct mention
  • Wedbush Adjusts BioCryst Pharmaceuticals Price Target to $20 From $21, Maintains Outperform Rating PositiveMT Newswires · 6 Aug 2026 · Related
  • Wedbush Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Cuts Target Price to $20 NegativeMarket news · 6 Aug 2026 · Direct mention
  • RBC Adjusts Price Target on BioCryst Pharmaceuticals to $13 From $14, Maintains Outperform Rating PositiveMT Newswires · 6 Aug 2026 · Related
  • TD Cowen Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $30Market news · 6 Aug 2026 · Direct mention
  • RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Raises Target Price to $14 PositiveMarket news · 7 Jul 2026 · Direct mention

Discussion

No comments yet — be the first to weigh in on BCRX.

Sign in to join the discussion.

Scroll to Top